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 ABSTRACT 
Introduction: Polycythemia vera (PV) is a bone marrow disorder that causes overproduction of 
red blood cells. While some studies have documented increased local incidence rates of PV, no 
study has explored the mortality rates of PV over time. Public health significance of this study is  
firstly examining PV mortality rates in detail; a better understanding of these rates may help 
contextualize changes. 
Methods: We used age-race-sex-and time period specific death counts from the Mortality and 
Population Data System (MPDS) from 1962 to 2009 for Pennsylvania (PA), California (CA), 
and the United States (US). Age-adjusted and age-specific mortality rates were examined for the 
whole US, as well as PA, California (CA), and the remaining US. We also accounted for changes 
in diagnostic criteria, International Classification of Diseases (ICD) mortality coding, and 
treatment. Negative binomial models were fit to account for age, sex, region, and critical time 
point changes in criteria, separated into seven sections to match events in PV medical history: 
1962-1967, 1968-1974, 1975-1977, 1978-1986, 1987-1998, 1999-2000, and 2001-2009. 
Results: We identified 18,743 PV death cases from 1962 to 2009; 95% of the deaths occurred in 
whites, and almost half of the deaths were in people 75 and older. Age-adjusted PV mortality of 
males decreased after 1967, while that of females decreased after 1978. The rate among males 
was always higher than that of females. Our time period analysis, corresponding to changes in 
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ICD coding, diagnostic criteria, and implementation of Hydroxyurea as standard treatment, 
found that each significantly influenced PV mortality. 
Conclusion: This study is the first comprehensive examination of PV mortality rates over time. 
We determined that acceptance of the PVSG diagnostic criteria in 1975 decreased the magnitude 
of the difference in PV mortality between males and females seen prior to 1975, apparently due 
to the introduction of sex-specific red cell mass values. The transition from the 8th to 9th ICD 
revision in 1979, in which PV was changed from malignant to “benign and/or uncertain and 
unspecified behavior”, decreased PV mortality significantly in both males and females. PV 
researchers should be aware of these changes when interpreting their data. 
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1.0  INTRODUCTION 
1.1 BACKGROUND  
 
Polycythemia vera (PV), a bone marrow disorder that causes overproduction of red blood cells as 
well as a slight increase in white blood cells and platelets, is one of the myeloproliferative 
disorders (MPD), which include chronic myeloid leukemia (CML), essential thrombocythemia, 
and primary myelofibrosis. [1] People with PV have a higher risk of thrombosis, which 
phlebotomy, chemotherapy (P32) and myelosuppressive drugs like Hydroxyurea and aspirin can 
control. [2] PV can lead to acute myeloid leukemia, myelofibrosis, and thrombosis, which is the 
formation of a blood clot inside a blood vessel and is the leading causes of death among PV 
patients. 
 
1.1.1 Mortality from PV 
Mortality from PV is based on information from death certificates. Cause of death is coded using 
the International Classification of Diseases, or ICD, codes published by the World Health 
Organization (WHO) and used worldwide for morbidity and mortality statistics, reimbursement 
systems, and automated decision support in health care. Because the ICD codes underwent 
several revisions between 1962 and 2009, the ICD codes of PV have changed as follows: 6th and 
7th revision, 294 polycythemia (1950-1967); 8th revision, 208 polycythemia vera (1968-1978); 
9th revision, 238.4 polycythemia vera (1979-1998); and 10th revision, D45 polycythemia vera 
(1999-2013). PV was classified generally as polycythemia (code 294) in the 6th and 7th ICD 
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revisions. In the 8th revision, PV was differentiated from secondary polycythemia. This 
differentiation is still present in the current 10th revision. From 1950 to 2009, the classification 
of PV altered, from malignant neoplasm to unspecified neoplasm in the 8th to 9th revision.    
 
1.1.2 Diagnosis of PV 
PV was initially described by Dameshek in 1951 as one spectrum of myeloproliferative diseases. 
[3] According to Dameshek, these interrelated disorders were due to some undiscovered stimulus 
acting on the bone marrow. In 1967, the Polycythemia Vera Study Group developed diagnostic 
criteria to recruit PV patients into clinical trials. In 1975, after a series of clinical trials from the 
late 1960s to early 1970s, these clinical diagnostic criteria, based on the concentration of 
hemoglobin and hematocrit (volume percentage of red blood cells in blood), were accepted as 
the first ones for PV. As shown in Table 1, the major criteria included a raised red cell mass 
(RCM), oxygen saturations, and splenomegaly [4]. The patients were diagnosed if they fit all the 
major criteria, or had a high red cell mass and oxygen saturation with two of the minor criteria. 
The PVSG criteria were the gold standard for PV clinical diagnosis in the 1970s and 1980s. 
Before 1975, US hematologists diagnosed PV patients using only one major criterion, raised red 
cell mass, and two of four minor criteria: thrombocytosis, leukocytosis, oxygen saturation 
(without overt lung disease or renal tumor), and splenomegaly.[4,22] During that time, the 
polycythemia cut-off value for males was over 55% hematocrit or 18g/100 ml of hemoglobin. 
The cut-off value for females was over 52% hematocrit or 17g/100ml hemoglobin. In 1975, the 
PVSG criteria were thought to be stringent enough to exclude a false positive. The 1975 criteria 
ruled out the common etiology of secondary polycythemia and required evidence of 
myeloproliferative state. 
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 Table 1 : 1975 PVSG diagnostic criteria 
A1 Raised red cell mass, male ≥ 36 ml/kg, female ≥ 32 ml/kg 
A2 Normal arterial oxygen saturation >92% 
A3. Splenomegaly 
B1. Thrombocytosis platelet count >400,000µl 
B2. Leukocytosis >12,000µl  
B3. Leukocyte alkaline phosphatase score >100  
B4. Serum B12 (>900pg/ml) or unsaturated B12 binding capacity (>2200pg/ml) 
Note: Diagnosis of PV if one of these combinations is present: 
A1+A2+A3;A1+A2+any two from B category 
 
With the passage of time, more recently developed tests superseded the first diagnostic 
criteria. [5] In 1996, Pearson and Messinezy produced a new set of diagnostic criteria that 
encompassed burst forming unit erythroid (also known as erythroid progenitor cell, which gives 
rise to colonies that only contain erythrocytes) growth and other advancements to problematic 
diagnostic individuals [6] (Table 2). Another criteria change was that the red cell mass (RCM) 
was measured in relation to surface area rather than ml/kg; a significant diagnostic reading was 
25% above the normal predicted value of red cell mass. In the 1975 PVSG criteria, the red cell 
mass value of obese people was underestimated due to being measured and then divided by 
weight. Also, these criteria differentiated secondary polycythemia from polycythemia vera, 
because secondary polycythemia is an acquired form of a rare disorder characterized by an 
abnormal increase in the number of mature red cells in the blood.  Those people who smoke, are 
obese, or have high blood pressure are at greater risk for secondary polycythemia. [7] In this 
version of the criteria, the absence of secondary polycythemia was explicitly noted, along with 
presence of high red cell mass, palpable splenomegaly, abnormal marrow karyotype, or any two 
of the minor criteria. 
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Table 2: : 1996 polycythemia vera clinical diagnostic criteria 
A1. Raised red cell mass (>25% above mean normal predicted value) 
A2. Absence of cause of secondary polycythemia 
A3. Palpable splenomegaly 
A4. Clonality marker (abnormal marrow karyotype) 
B1. Thrombocytosis platelet count >400,000 / µl 
B2. Neutrophil leukocytosis count > 10,000 / µl 
B3. Splenomegaly demonstrated on isotope or ultrasound scanning 
B4. Characteristic BFU-E growth or reduced serum erythropoietin 
Note: Diagnosis of PV if one of these combinations is present:  A1+A2+A3 or A4; 
A1+A2 + two of B category 
 
As shown in Table 3, in 2001, the World Health Organization (WHO) published new 
criteria for PV. These criteria showed significant changes in the measurement of RCM (adding 
new diagnostic criteria considering age, gender, and regional factors based on the population 
average value) and endogenous erythroid colony (EEC) formation. [6] The bone marrow produces 
endogenous erythroid colonies (EED) in the absence of exogenous erythropoietin (drugs have 
structure similar to erythropoietin that can control blood cell production). These criteria differed 
from the 1996 criteria in three main aspects: 1) the major criterion of red cell mass was defined 
less stringently; 2) the elevation of EEC formation went from a minor criterion to a major one; 
and 3) the WHO criteria included bone marrow biopsy as a minor criterion. People without 
secondary polycythemia but with a high total blood cell mass and any one of the other major 
criteria or any two of the minor criteria would receive a diagnosis of PV. 
 
 
 
 
 
 
 
 4 
 Table 3 : 2001 WHO diagnostic criteria 
A1. Elevated total blood cell mass >25% above mean normal predicted value, or 
hemoglobin >18.5g/dl in men, 16.5 g/dl in women or >99th percentile of method-specific 
reference range for age, sex and altitude of residence 
A2. No cause of secondary erythrocytosis 
A3. Splenomegaly 
A4. Clonal genetic abnormality other than Philadelphia chromosome or Bcr-Abl fusion 
gene in marrow cells 
A5. Endogenous erythroid colony formation in vitro 
B1. Thrombocytosis platelet count >400,000µl 
B2. Leukocytosis >12,000µl 
B3. Bone marrow biopsy showing panmyelosis with prominent erythroid and 
megakaryocytic proliferation 
B4.Low serum erythropoietin levels 
Note: Diagnosis of PV if one of these combinations is present: A1+A2 and any other 
category of A; A1+A2 and any two of category B 
 
In 2005, multiple research studies identified a mutation in JAK2 V617F on the JAK2 gene 
in large numbers of MPDs patients. [8-10]. This mutation enhances kinase activity, which causes 
hyper-activation of erythropoietin, or overproduction of the red cells. [11] Scientists discovered 
that somatic JAK2 mutations can be observed in 65-97% of PV patients, in 23–57% of ET 
patients, as well as in 35–57% of patients with other myeloid neoplasms [12]. Although this 
genetic mutation cannot differentiate MPDs from one another, it can be used to rule out the 
possibility of reactive thrombocytosis or myelofibrosis. [13] When the typical blood profile is 
obscured, the JAK2 mutation becomes the only way to establish the diagnosis. [14] In a genetic 
analysis of PV patients, no association was observed between mutational status and current age, 
diagnostic age, gender, race, or self-reported family history; hence, it was suggested that the 
mutation is acquired. [6] 
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In 2008, WHO added this genetic mutation to the PV diagnostic criteria, so that 
molecular tools could more effectively help pinpoint the disease (Table 4). The most significant 
change of this version of criteria was adding the JAK2 mutation to the major criteria. People who 
met both major criteria would receive a diagnosis of PV. Those who met the first major criteria 
(high total blood cell mass) would need any two of the minor criteria to be diagnosed with PV. 
 
Table 4 : 2008 WHO diagnostic criteria 
A1. Elevated total blood cell mass >25% above mean normal predicted value, or 
hemoglobin >18.5g/dl in men, 16.5 g/dl in women or >99th percentile of method-specific 
reference range for age, sex and altitude of residence 
A2. Presence of JAK2V617F or similar mutation  
B1. Bone marrow trilineage myeloproliferation 
B2. Subnormal serum Epo level 
B3. EEC growth 
Diagnosis of PV requires meeting either both A criteria and one B criterion or the first A and 2 B 
criteria. 
 
1.1.3 Treatment of PV 
Although there is no cure for PV, hematologists have found ways to extend the survival time of 
PV patients. Because thrombosis is the main cause of PV death, hematologists targeted treatment 
of thrombocytosis. Eighty percent of the clinicians used phlebotomy alone, phlebotomy 
combined with Hydroxyurea, or Hydroxyurea alone to treat PV patients. Aspirin, Interferon, 32P, 
and Busulfan were chosen only in special situations in clinical practice.  . Hydroxyurea plays a 
significant role among the drugs to treat PV because it has fewer side-effects compared to other 
drugs. Since 1987, Hydroxyurea has been widely used to treat high thrombosis risk patients 
because it has less risk of causing acute leukemia than other drugs, like Busulfan.[11]  
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1.1.4 Epidemiology of PV 
PV is rarely found in children or adults younger than thirty years of age. Only 5% of patients 
diagnosed with PV are younger than forty-years-old. The incidence of PV increases with age; the 
average diagnostic age is seventy-years-old. Reports from Europe indicate that the annual 
incidence rates for PV are variable, ranging from 0.02 to 2.8 per 100,000 inhabitants. [15] Most 
reports demonstrated that the incidence rates do not differ between genders, although some 
studies report that males have a higher occurrence. [5, 12] The highest reported annual incidence 
was 23.5/100,000 among 70-79-year-old males. [16] The prevalence of PV was 30 cases/100,000 
inhabitants in the U.S [17]. 
The median survival time for untreated PV patients is 18 months, compared to 15 years 
for those treated.[2] It is recommended that all patients undergo phlebotomy, with the goal of 
keeping the hematocrit value below 0.45; stable patients who are at low risk for thrombosis do 
not require additional therapy. For those at high risk for thrombosis, the choice of a 
myelosuppressive agent depends on the patient’s age or history of thrombosis. However, these 
myelosuppressive drugs have potential side effects, including leukemia. [2]  
In 2004, four cases of PV found in people living on the same rural road near Tamaqua, in 
Northeastern Pennsylvania (PA), triggered the Pennsylvania Department of Health (PADOH) to 
review cancer cases reported to the Pennsylvania Cancer Registry (PCR) from the three counties 
(Carbon, Luzerne, and Schuylkill) surrounding the Tamaqua areas. The PADOH found that the 
overall cancer rate in the areas was similar to that in other parts of the state, but there were more 
PV cases than expected.[18] The PADOH invited the Agency for Toxic Substances and Disease 
Registry (ATSDR) to perform an extensive case-finding effort in the tri-county areas. The 
ATSDR used PCR records, outreach to hematologists, and case self-identification to determine 
cases diagnosed from 2001 to 2005 in the tri-county areas.  The ATSDR identified a statistically 
significant (p < 0.001) cluster of 15 PV cases in the Tamaqua community. [18]The investigators 
also found that almost half of the confirmed PV cases had not been reported to the PCR, while a 
third of the participants who reported to the registry with a hybrid clinical diagnosis of PV did 
not meet PV diagnostic criteria before 2004. [18] Most of the population-based PV studies have 
focused on PV incidence. In 1994, a retrospective study based on the local clinical medical 
records found that the sex- and age-adjusted incidence of PV in Olmsted County, Minnesota, was 
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1.9 per 100,000 population per year from 1935 to 1989; during this period, this rate hovered 
around the average incidence. The age and sex adjusted incidence was 2.0, 1.1, 2.8, and 1.9 per 
100,000 population per year in 1950-1959, 1960-1969, 1970-1979, and 1980-1989, respectively. 
[16]During this study, potential cases of PV were observed than 55 cases were diagnosed by 1975 
diagnostic criteria. Additionally, in Malmo, Sweden, this incidence rate was 1.0 to 2.6 per 
100,000 population per year with an increasing pattern from 1950 to 1984.This retrospective 
study also based on the local hospital records, and they were identified 177 PV patients by PVSG 
criteria.  No examination of PV mortality in the US can be found. 
While studies, such as the one focusing on PV in Northeastern PA, have documented 
increased local incidence rates of PV, no study has explored the mortality rates of PV over time. 
This study will be the first attempt to examine PV mortality rates in detail; a better understanding 
of these rates will help contextualize the changes of PV-associated rates. 
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2.0  METHODS 
2.1.1 Objectives 
As no epidemiological study has focused on examining PV morality changes on a large scale, 
this research will be the first attempt to describe and analyze PV mortality trends in different 
gender-race groups from 1962 to 2009 in Pennsylvania and in the United States. The recent 
findings of increased PV incidence in Northeastern PA led us to investigate whether PV 
mortality rates in PA are significantly different from those in other parts of the US. In the 
medical history of PV from 1962 to 2009,.diagnostic criteria has changed two times. At first, 
there were only clinical measurements; after several PVSG clinical trials, PVSG criteria in 1975 
was accepted for diagnosing PV more specifically; as cellular and genetic methods developed, 
WHO published in 2001 new PV criteria. These changes may have affected mortality rates by 
improving case ascertainment. As the clinical trials progressed, researchers found that 
Hydroxyurea reduced the risk of death from PV-related thrombosis with few side effects. Wide 
usage of Hydroxyurea may have affected PV mortality rates by increasing survival time for PV 
patients. From 1962 to 2009, ICD codes have changed three times (in 1968, 1978, and 1999 
respectively); these changes may cause discontinuity in the cause-specific mortality trends. This 
research will analyze the influences of the three above factors by modeling and comparing the 
results with graphical study. 
2.1.2 Research design 
In this study, data were evaluated for the Pennsylvania, California, and the United States. Our 
target population for analysis was PA mortality. We first examined descriptive mortality graphs 
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to show how PV mortality rate altered from 1962 to 2009. Then, a generalized linear model was 
fit to find what influenced the rate of PV mortality. During the model building, we used the US 
population to compare with the PA population to determine if PA had a different mortality 
pattern from the US. Also, we compared PA and CA because California has no known incidence 
of increased risk of PV, and California also has a larger population than PA, which could 
produce more stable estimates of mortality. With these comparisons, we want to detect if PA had 
different mortality patterns from other areas or if the high incidence pattern only happened in 
that cluster in PA.  
In the model, we had six predictors: age, region, sex, ICD code revision (four segments), 
diagnostic criteria changes (three segments), and treatment of Hydroxyurea (two segments). 
During the model building process, we ran univariate models to first show the direction of the 
predictors’ influence; we then modeled the ICD code revision changes, diagnostic criteria 
changes, and usage of treatment combined with other predictors. After that, we built region-
specific models to test the effects of these changes to the three regions. Finally, we built the 
model with predictors’ region, age, sex, and a categorical time variable with seven segments to 
include all the changes in time in order to reduce the influence of the overlapping time periods if 
we had included all three time variables in one model. 
 
2.1.3 Data source 
The Mortality and Population Data System (MPDS) was used to generate the cancer mortality 
rates for the priori cause of interest mortality from PV International Classification of Disease 
(ICD) 7th revision codes 294; (ICD) 8th revision 208; (ICD) 9th revision 238.4; and (ICD) 10th 
revision D45. MPDS, a data repository and retrieval system for detailed mortality data provided 
by the National Center for Health Statistics and the US Census Bureau, has been maintained in 
the Biostatistics Department of the University of Pittsburgh since the 1980s. The MPDS contains 
the underlying cause of death codes (ICD four-digit codes) for all persons who died in the United 
States from 1950 to 2009 (limited to deaths from malignant neoplasms during the 1950-1961 
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period). Individual death records include codes for gender, race, age of death, year of death, and 
geographic location (at time of death). 
In this thesis, the exact count data of death and population were used to calculate the mortality 
rates and build the model. Table 5 shows the specific coded causes of death for PV.      
PV was classified generally as polycythemia (code 294) in the 6th and 7th ICD revisions. In 
the 8th revision, PV was differentiated from secondary polycythemia. This differentiation is still 
present in the current 10th revision. From 1950 to 2009, the classification of PV altered, from 
malignant neoplasm to unspecified neoplasm in the 8th to 9th revision.    
Table 5: ICD codes used in mortality analysis of PV 
6th & 7th 
revision(1950-1967) 
8th revision 
(1968-1978) 
9th revision 
(1979-1998) 
10th revision 
(1999- ) 
294 
polycythemia 
208 
polycythemia vera 
238.4 
polycythemia vera 
D45 
polycythemia vera 
2.1.4 Summary of age covariates 
Initially, we combined the age group under 45 because we knew that 95% of PV patients are 
older than 40. After calculating the age-specific mortality of different age strata with the date of 
white males and females in the three populations, we found that ages 45-54, 55-64, and 65-74 
had a similar mortality change trend, while the 75-84 and the 85+ age groups showed a 
different trend compared with the younger age groups . The PA group of both white males and 
females 75 and older varied around average. PV mortality of CA white males 75 and older 
varied and declined, and that of corresponding females showed an inverse bathtub pattern. 
Although the mortality patterns differed according to regions and genders in the over 75 
group, the 45-74 subgroups in these six region-gender groups showed similar declining 
patterns of  PV mortality (Figure 1). For the less than 45 age group the mortality is close to 
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zero; it appeared as a stable line. Therefore, we summarized the data according to the 
following three age groups: less than 45, 45 to 74, over 75. After summarizing the data, we 
found that the mortality trends in the three age categories differed.  The mortality rate in US 
white males ages 75 and older in areas of the US outside PA and CA increased from 1962 to 
1967, and then decreased from 1968 to 2009. The mortality rate in US white females ages 75 
and older in areas of the US outside PA and CA increased from 1962 to 1977, and then 
decreased from 1978 to 2009. varied (Age-specific mortality tables also appear in the 
Appendix.)  
When calculating the mortality rates, we separated the time period into seven sections to 
match the events in PV medical history: 1962-1967, 1968-1974, 1975-1977, 1978-1986, 1987-
1998, 1999-2000, and 2001-2009. 
Figure 1:  Age-specific mortality for ungrouped data of Other US white males 
In white males in other areas of the US, whose age in 65 to 74, 55 to 64, 45 to 54 
groups, PV mortality decreased after 1967. In the 75 to 84 age group, PV mortality 
increased from 1962 to 1967 then decreased. In the over 85 age group, PV mortality 
increased from 1962 to 2001 then decreased. (Figure 1) 
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Figure 2: Age-specific mortality for grouped data of Other US white males 
 
PV mortality of US males 75 and older increased from 1962 to 1974, and then decreased; 
PV mortality of US males 45-74 continued to decline. (Figure 2) 
 
Figure 3:  Age-specific mortality for ungrouped data of Other US white females 
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In white females in other areas of the US, whose age in 65 to 74, 55 to 64, 45 to 54 
groups, PV mortality decreased after 1975. In the 75 to 84 age group, PV mortality increased 
from 1962 to 1975 then decreased. In the over 85 age group, PV mortality increased from 1962 
to 2001 then decreased. (Figure 3) 
 
Figure 4: Age-specific mortality for grouped data of Other US white females 
 
PV mortality of US females 75 and older increased from 1962 to 1977, and then 
decreased; again, PV mortality of US females 45-74 kept decreasing. (Figure 4) 
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 Figure 5:  Age-specific mortality for ungrouped data of PA white males 
 
In PA white males, whose age in 75 to 84, 65 to 74, 55 to 64, 45 to 54 groups, PV 
mortality decreased after 1968. In the 75 to 84 age group, PV mortality varied and decreased. In 
the over 85 age group, PV mortality increased from 1962 to 197,  then varied and decreased. 
(Figure 5) 
 
Figure 6 : Age-specific mortality for grouped data of PA white males 
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PV mortality of PA males 75 and older did not have an obvious trend; PV mortality of 
PA males 45-74 continued to decline.(Figure 6) 
 
Figure 7:  Age-specific mortality for ungrouped data of PA white females 
In PA white females, whose age in 55 to 64, 45 to 54 groups, PV mortality decreased 
after 1962. In the 65 to 74 and 75 to 84 age group, PV mortality increased from 1962 to 1968 
then decreased and varied. In the over 85 age group, PV mortality increased from 1962 to 1999 
then decreased. (Figure 7) 
 
Figure 8: Age-specific mortality for grouped data of PA white females 
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PV mortality of PA females 75 and older did not have an obvious trend; PV mortality of 
PA females 45-74 continued to decline.(Figure 8) 
 
 
Figure 9:  Age-specific mortality for ungrouped data of CA white males 
In CA white males, whose age in 65 to74, 55 to 64, 45 to 54 groups, PV mortality 
decreased after 1962. In the 65 to 75 to 84 age group, PV mortality increased from 1962 to 1975 
then decreased. In the over 85 age group, PV mortality varied from 1962 to 2009. (Figure 9) 
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 Figure 10: Age-specific mortality for grouped data of CA white males  
 
PV mortality of CA males 75 and older decreased after 1975; PV mortality of CA males 
45-74 continued to decline.(Figure 10) 
 
Figure 11:  Age-specific mortality for ungrouped data of CA white females 
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In CA white females, whose age in 65 to 74, 55 to 64, 45 to 54 groups, PV mortality 
decreased after 1962. In the 75 to 84 age group, PV mortality increased from 1962 to 1968 then 
decreased and varied. In the over 85 age group, PV mortality increased from 1962 to 19 then 
decreased and varied. (Figure 11) 
 
Figure 12: Age-specific mortality for grouped data of CA white females 
 
PV mortality of CA females 75 and older increased from 1962 to 1977, and then 
decreased; again, PV mortality of CA females 45-74 increased from 1962 to 1974, and then 
decreased. (Figure 12) 
 
2.1.5 Death count summary  
Death counts were summarized in different categorical variables (Table 6). In the 18,743 PV 
death cases from 1962 to 2009, 95% of the deaths occurred in white males and females, 97% of 
the deaths affected people 45 and older, and almost half of the deaths were concentrated in 
people 75 and older. Males and females had a very similar death count.  The counts of death 
were evenly distributed in the time period divided by the ICD revision. Two-thirds of the deaths 
were distributed before the wide usage of Hydroxyurea (1987), and almost 90% of deaths were 
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distributed before the publication of the 2001 WHO criteria. The three regions had similar 
distributions of death counts in these covariates. 
Table 6: Descriptive characteristics of covariates 
  
CA 
 
PA 
 
OTHER TOTAL 
  
No. % No. % No. % 
 Death Total 1623 
 
1172 
 
15948 
 
18743 
Race  W 1539 94.8 1118 95.4 15102 94.7 17759 
 
 NW 84 5.2 54 4.6 810 5.3 948 
Gender  Male 787 48.5 609 52 7945 49.8 9341 
 
 Female 836 51.5 563 48 8003 50.2 9402 
Age group  <45 51 3.1 39 3.3 520 3.3 610 
 
 45-74 706 43.5 597 50.9 7913 49.6 9216 
 
 75+ 866 53.4 536 45.7 7515 47.1 8917 
ICD changes  6th-7th(1962-1967) 262 16.1 255 21.8 2934 18.4 3451 
 
 8th(1968-1978) 485 29.9 323 27.6 4537 28.4 5345 
 
 9th(1979-1998) 586 36.1 422 36 5641 35.4 6649 
 
 10th (1999-) 290 17.9 172 14.7 2836 17.8 3298 
Diagnostic 
changes 
 
 
BEFORE PVSG(1962-
1974) 608 37.5 489 41.7 6199 38.9 7296 
 
 PVSG(1975-2000) 803 49.5 561 47.9 7775 48.8 9139 
 
 WHO(2001-) 212 13.1 122 10.4 1974 12.4 2308 
Treatment 
changes 
 
 
BEFORE HU(1962-
1986) 1015 62.5 759 64.8 9960 62.5 11734 
 
 HU(1987-) 608 37.5 413 35.2 5988 37.5 7009 
 
The mortality graphs of non-white people and those individual in the <45 age group are 
not shown as there are too many zero values in the data. The age-adjusted mortality for all race-
gender-age groups is shown in Appendix I. 
Age-adjusted mortality (0.35 /100,000 population per year) is much lower than that of 
unadjusted mortality (1~2/100,000 population per year). This situation is due to the 
concentration of deaths in a small proportion of people: less than 5% of people are 75+ in the 
population, but this group represents approximately half of the PV deaths overall (Table 7). The 
complete death count data summary is shown in Appendix II. 
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 Table 7:  Death distribution in age group 
Region  Gender  Age  
                 death 
count 
Population 
percent in the 
age (%) 
US  FEMALE  <45  173 65.3 
 
 
 
 45-74  3300 28.5 
 
 
 
 >75  4530 6.2 
 MALE  <45  347 69.4 
 
 
 
 45-74  4613 26.8 
 
 
 
 >75  2985 3.8 
PA  FEMALE  <45  13 61.5 
 
 
 
 45-74  211 31.2 
 
 
 
 >75  339 7.3 
 MALE  <45  26 66.2 
 
 
 
 45-74  386 29.5 
 
 
 
 >75  197 4.4 
CA  FEMALE  <45  13 67.8 
 
 
 
 45-74  301 26.7 
 
 
 
 >75  522 5.5 
 
 MALE  <45  38 71.9 
 
 
 
 45-74  405 24.7 
 
 
 
 >75  344 3.4 
 
Because we observed too many zero values in the non-white population and detected 
95% of the deaths among whites, we decided to only use white population data to build our 
model. From the background information, we knew that 95% of the PV patients are over 40- 
years-old; therefore, we combined all age groups under 45. Even when combined, these age 
groups demonstrated a very small proportion of the overall death count. (Table 7) 
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2.1.6 Distribution of death count 
After we summarized the death count, we had 126 observations in the dataset. (We summarized 
the death count by gender in 2 category, age in 3 categories, region in 3 categories, 3 time 
variables in 7 categories.) Because the test for the normal distribution of the count data rejects 
the null (p<0.001) (Fig 13), and the dependent variable is count data, but not dichotomized 
classified data, we rejected the possibility of using a linear regression or logistic regression to 
model the data. Usually, the Poisson model would be used to model count data, but in our 
dataset, the mean of the grouped death count is 148.75, while the variance is 70,901. The data are 
extremely over-dispersed, thereby violating the null hypothesis of the Poisson distribution. These 
data had five zero values in the 126 observations; thus, zero-truncated and zero-inflated problems 
did not occur. 
 
 
Figure 13: Death count distribution of PV 
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2.1.7 Descriptive analyses 
The descriptive statistics analysis was primarily used to investigate age-adjusted mortality in 
different age-gender-race groups by year. The whole population was separated into 12 age 
groups: less than 5, 5-9, 10-14, 15-19, 20-24, 25-34, 35-44, 45-54, 55-64, 65-74, 75-84, and 85 
and older. Four race-gender groups were used: white males, white females, non-white males, and 
non-white females.  
The graphs are drawn in two parts: the first one is for the whole US, while the second and 
third ones show PA, CA, and the US minus PA and CA by gender. The graphs separately show 
age groups less than 45-years-old and over 45-years-old as most PV deaths were observed 
among those over 40-years-old.  
The age-adjusted mortality was calculated by the formula below: 
Ri = (n / N) *w,  
R = ΣRi  (i =12), 
In the formula, Ri is the weighted mortality in the ith age group, R is the age-adjusted mortality, n 
is the exact count of death of PV in this age-gender-race subgroup in that year, N is the number 
of population in this age-gender-race subgroup in that year, and w is the weight function that was 
calculated using the US age-gender-race specific population in the matching year as the standard 
population. In the graph of US white males and females, mortality is adjusted using the 1980 
population. 
The descriptive statistics also include a summary of the exact count of PV deaths by race-
gender groups in the PA, US, and CA population in each year. In this part, age groups are 
separated into three groups: less than 45, 45-74, and 75 and older. This step helps identify the 
zero inflated issue for the Poisson model building in the next step. 
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2.1.8 Data analysis 
 
Poisson regression is usually used in mortality studies. This technique is a branch of the 
generalized linear model, in which the outcome (number of deaths) is count data following the 
Poisson distribution. Epidemiological studies since the 1980s, especially cancer mortality 
studies, have used this method. [19] The assumption is when the number of deaths (d) is small 
relative to the total cohort size (n), the Poisson approximation to the exact sampling distribution 
of  λ = d/n will be sufficient. That means when d is small, withdrawing the deaths from future 
person-years is acceptable and the number of deaths in different cells can be considered to be 
statistically independent. 
The following model is used: 
Log E(d) = log(n) + xb 
Whereas d is the summarized death from a specified group, n is the person-year at risk, and b 
represents a vector of regression coefficients describing the effects of primary interest.[18] 
However, from Figure 13, we see that a significant number of small count values existed; 
at the same time, extreme large values were distributed sparsely. Among these small counts, 
there were only five zero value counts; as a result, the issue of zero-inflated or zero-truncated 
problem did not exist, but overdispersion did exist. To fix the overdispersion problem, we 
decided to determine whether the use of the overdispersion Poisson regression or negative 
binomial regression would be more appropriate to model these data.  
An assumption of over-dispersed Poisson regression is that the variance is proportional to 
the mean: 
Var(Y) = ϑE(Y) = ϑμ (ϑ>1, we have overdispersion). 
An assumption of negative binomial regression is that:  
Var(Y ) = μ(1 + αμ). (If α >0, overdispersion exists.) 
 
To determine whether the over-dispersed Poisson model or negative binomial model 
would be better, we fit three multivariate models, including age, gender, and region, and one of 
the time-period categorical variables. After that, we compared the AIC and BIC values of the 
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two series of models. After comparing the results, we chose to use negative binomial regression 
as it had smaller AIC and BIC values in this situation. (Table 8) 
 
Table 8: Comparison of AIC/BIC value of overdispersed Poisson model and negative binomial model 
 
 
Negative 
binomial Over-dispersed Poisson  
 
 AIC BIC           AIC             BIC 
 
     
R+A+S+T1  1046.21 1074.6 2465.52 2491.07 
 R+A+S+T2  1098.93 1124.46 3044.58 3067.27 
 R+A+S+T3  1084.23 1106.92 3659.75 3679.6 
 
     
 
R =REGION A= AGE S = SEX T1 = ICD CODES T2 = Diagnostic criteria change T3 = Treatment 
Since our research goal is to determine whether PV deaths in PA differed from PV deaths 
in other places in the US, we have a predictor for region and several potential confounders (age, 
gender, times of ICD codes changes, times of diagnostic criteria changes e, time when  
Hydroxyurea became widely used). Table 9 lists how these independent variables were coded. In 
the model building, we first used univariate testing to see the direction of the influences of these 
predictors. Then, we built multivariate models to see how these predictors affect the overall 
mortality. In this step, we included interaction terms to detect the different influences of these 
time categorical variables given different regions or genders. Finally, we built region-specific 
models to see the different appearance if the influences of the other areas were removed. In the 
region-specific models, only the US, PA, or CA data were used (42 observations in each model). 
These region-specific models were also built separately by three time categorical variables with 
age and gender in the model. 
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 Table 9: Variable codes for analysis 
variable different level 
  sex  female = 0  male = 1 
 
 
       
age  <45 = 0  45-74 = 1 >75 = 2  
 region  other = 0  PA = 1 CA = 2  
        
ICD  6&7th = 0  8th = 1 9th = 2  10th = 3 
diagnostic criteria  before PVSG = 0  PVSG = 1 WHO = 2  
 treatment  before HU = 0  HU = 1 
 
 
     
 
 
 26 
3.0  RESULT 
3.1 GEOGRAPHICAL STUDIES 
PV mortality in the US (in this section, ‘US’ means the whole US) decreased from 1962 to 2009. 
As the graphs indicate, several different time segments occurred. The graphs also illustrate when 
Hydroxyurea was widely used. These graphs indicate that PV mortality of white males was 
always higher than that of white females. However, the difference of the rates between genders 
dropped quickly after 1975, the time when the PVSG criteria were accepted. Also, the rates of 
PV mortality in white males and females dropped sharply after 1978, the time when the ICD 
revision changed from the 8th to the  9th (Figure 14). Age-adjusted mortality was adjusted to the 
1980 US population here. 
 
 
Figure 14:  Comparison of Age-adjusted mortality of US white male and female 
A comparison of PV mortality of white males in three different regions (PA, CA, other 
areas of the US) shows that mortality in PA is higher than that of the other two areas before 
1980. After 1986, the mortalities of the three regions were very similar. PV mortality of white 
males in the three regions decreased from 1962 to 2009 (Fig 15). 
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   Figure 15:  Comparison of Age-adjusted mortality of white males in PA, CA, and other areas in the US 
A comparison of PV mortality of white females in three different regions (PA, CA, 
other areas of the US) shows that the mortality rates of the three groups were also similar. 
These rates of white females in the three regions slightly decreased from 1962-2009 (Fig 16). 
Figure 16:  Comparison of Age-adjusted mortality of white females in PA, CA, and other areas in the US 
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3.2 MODEL BUILDING 
3.2.1 Univariate negative binomial models 
Tables 16 to 21 show the univariate models of predictors and confounders. We placed more 
emphasis on the strength and direction of the influence of these predictors than on the statistical 
significance. In this section, the baseline ‘US’ population excludes both the PA and CA 
populations.  
Age has a large positive influence on PV mortality; the people in the 75+ age group 
(coefficient = 5.24) were more likely to die due to PV than people whose ages ranged from 45 to 
74 (coefficient = 3.61). The P-value of age demonstrates that age is a significant predictor of PV 
mortality. The trend test was statistically significant, indicating that PV mortality increases as 
people age (Table 10). 
Table 10: Negative binomial regression on single variable: age 
  β p-value global test trend test 
age <45 0 - <0.001 <0.001 
 45-74 3.61 <0.001   
 75+ 5.24 <0.001   
constant  -16.2    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Compared to other areas in the US, PA had a lower mortality from PV (coefficient = -
0.01); similarly, CA also had a lower mortality when compared to the remainder of the US 
(coefficient = -0.01). However, this predictor was not statistically significant (Table 11). 
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Table 11: Negative binomial regression on single variable: region 
  β p-value global test 
region US 0 - 0.997 
 PA -0.01 0.982  
 CA -0.01 0.982  
constant  -11.87   
 
Compared to females, males had a higher mortality from PV although the difference was 
not statistically significant (coefficient = 0.21). (Table 12) 
 
Table 12: Negative binomial regression on single variable: sex 
  β p-value 
sex female 0 - 
 male 0.21 0.475 
constant  -11.99  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
After the first ICD code revision, PV mortality slightly increased, and then decreased 
after the other two revisions (Table 13). This pattern of change matches what we observed in the 
age-adjusted PV mortality graph of US white males(Table 13). ICD code revision is not a 
statistically significant predictor in this model. The trend test is statistically significant, 
indicating that  PV mortality decreased as ICD code changed. 
 
Table 13: Negative binomial regression on single variable: ICD code revision 
  β p-value global test trend test 
ICD 6&7th  0 - 0.1684 0.029 
 8th(1968) 0.07 0.875   
 9th(1979) -0.38 0.402   
 10th(1999) -0.72 0.124   
constant  -11.64    
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After every change in PV diagnostic criteria, the mortality decreased (Table 14). 
Diagnostic criteria changes were not statistically significant. 
 
Table 14: Negative binomial regression on single variable: diagnostic criteria 
  β p-value global test trend test 
diagnostic 
criteria 
before PVSG 0 - 0.2048 0.142 
 PVSG(1975) -0.36 0.275   
 WHO(2001) -0.81 0.079   
constant  -11.59    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Furthermore, after wide usage of Hydroxyurea by clinicians, PV mortality decreased 
(Table 15)..  This predictor is statistically significant. 
 
Table 15: Negative binomial regression on single variable: treatment 
  β p-value 
treatment before HU 0 - 
 HU(1987) -0.6 0.037 
constant  -11.66  
3.2.2 Time categorical negative binomial models 
Our final negative binomial regression models are listed in Tables 16-18. The model selection 
method was backward selection. Although region and the three time variables were not 
statistically significant in the univariate model global test, they were our research targets. So we 
included these factors in the beginning then did backward selection. The results of the test of α 
were all statistically significant, which indicated that the variance is a quadratic form of the mean. 
The age, gender, and time categorical variables were statistically significant in the three models. 
Region was only significant in the ICD code revision model. 
In the modeling of ICD codes revision, PV mortality in PA is not statistically significant 
different from that in other areas of the US; the ICD codes revision from 7th to 8th did not 
statistically significantly reduce the PV mortality. We also tested the difference of different 
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levels in the categorical variables and found that after the ICD code 9th revision and 10th revision, 
PV mortality differed.  PV mortality in PA and CA were statistically significant different. (Table 
16) 
We also tested the interaction terms between time variables and region in the following 
models, however, none of them was statistically significant. 
 
Table 16:   Negative binomial regression model for ICD code revision 
  β sig level test of 
previous 
category 
global test trend test 
age <45 0 -  <0.001 <0.001 
 45-74 3.63 0.048    
 75+ 5.55 <0.001 <0.001   
sex female 0 -    
 male 0.37 <0.001    
ICD code 6&7th  0 -  <0.001 0.029 
 8th (1968) -0.155 0.158    
 9th (1978) -0.96 <0.001 <0.001   
 10th (1999) -1.42 <0.001 <0.001   
region OTHER 0 -  0.0338  
 PA 0.04 0.553    
 CA -0.23 0.04 0.016   
constant  -15.91 <0.001    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In the modeling of diagnostic criteria, neither PA nor CA had statistically significant 
difference in PV mortality compared to other areas of the US. We also tested the difference of 
different levels in the categorical variables and found that after the WHO criteria acceptance, the 
PV mortality differed. PV mortality in PA and CA were not statistically significant different. The 
interaction between gender and criteria changes here indicated that PV mortality of white males 
decreased more than those of white females after acceptance of PVSG criteria (Table 17). 
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Table 17: Negative binomial regression model for diagnostic criteria change 
  β sig level test of 
previous 
category 
global test trend 
test 
age <45 0 -  <0.001 <0.001 
 45-74 3.63 <0.001    
 75+ 5.51 <0.001 <0.001   
sex female 0 -    
 male 0.39 <0.001    
diagnostic 
criteria  
BEFORE PVSG 0 -  <0.001 0.142 
 PVSG (1975) -0.81 <0.001    
 WHO (2001) -1.47 <0.001 <0.001   
region OTHER 0 -  0.13  
 PA 0.05 0.997    
 CA -0.16 0.29 0.06   
sex#criteria female#before 
PVSG 
0 -   
 male#PVSG -0.47 0.01    
 male#WHO -0.41 0.12    
constant  -15.95 <0.001    
  
In the modeling of treatment, neither PA nor CA had statistically significant differences 
in PV mortality as compared with other areas of the US. We also tested the difference of 
different levels in the categorical variables and found that PV mortality in PA and CA were 
statistically significant different (Table 18). 
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Table 18: Negative binomial regression model for treatment 
β sig level test of 
previous 
category 
global test trend test 
age <45 0 - <0.001 <0.001 
45-74 3.62 <0.001 
75+ 5.51 <0.001 <0.001 
sex female 0 - 
male 0.39 <0.001 
Treatment before HU 0 - 
HU (1987) -1.04 <0.001 
region OTHER 0 - 
PA 0.06 0.554 0.06 
CA -0.18 0.074 0.027 
constant -16.15 <0.001 
3.2.3 
3.2.3 Region-specific models 
From Table 19, we found that all of the predictors (age, gender, and ICD codes revision), 
significantly affected PV mortality. The influence of the first revision of ICD codes in PA was 
greater than that of CA and other US areas. In the three populations, the first revision of  ICD 
codes did not significantly affect PV mortality. Comparing the three models, we observed that 
PA white males had a higher ratio of PV mortality than that of white males in CA and other areas 
of the US. In CA, people 75 and older had a higher mortality ratio than in PA and other areas of 
the US. Tests between the three times of the ICD code revision showed that after each change, 
PV mortality statistically significant decreased.
Table 19: Region- specific model for ICD code revision 
US  β sig level test of 
previous 
category 
global test trend test 
age <45 0 -  <0.001 <0.001 
 45-74 3.69 <0.001 <0.001   
 75+ 5.54 <0.001    
sex female 0 -    
 male 0.36 0.001    
ICD code 6&7th    <0.001 0.16 
 8th(1968) -0.16 0.335 <0.001   
 9th(1979) -1.04 <0.001 <0.001   
 10th(1999) -1.38 <0.001    
constant  -15.91 <0.001    
PA  β sig level test of 
previous 
category 
global test trend test 
age <45 0 -  <0.001 <0.001 
 45-74 3.46 <0.001    
 75+ 5.24 <0.001 <0.001   
sex female 0 -    
 male 0.44 0.001    
ICD code 6&7th 0 -  <0.001 0.103 
 8th(1968) -0.25 0.237    
 9th(1979) -0.84 <0.001 <0.001   
 10th(1999) -1.33 <0.001 <0.001   
constant  -15.72     
CA  β sig level test of 
previous 
category 
global test trend test 
age <45 0 -  <0.001 <0.001 
 45-74 3.64 <0.001    
 75+ 5.77 <0.001 <0.001   
sex female 0 -    
 male 0.32 0.004    
ICD code 6&7th 0 -  <0.001 0.21 
 8th(1968) -0.06 0.733    
 9th(1979) -0.94 <0.001 <0.001   
 10th(1999) -1.51 <0.001 <0.001   
constant  -16.18     
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From Table 20, we found that after the acceptance of the PVSG diagnostic criteria, PV mortality 
in all of the regions decreased, although the mortality in PA decreased less than that of CA and 
the rest of the US. Comparing the three models, we observed that PA white males had a higher 
ratio of PV mortality than white males in CA and other area of the US. In CA, people 75 and 
older had a higher mortality ratio than those in the same age group in PA and other areas of the 
US. Tests between the two times of diagnostic criteria change showed that after the acceptance 
of the WHO criteria, PV mortality statistically significant decreased. 
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Table 20: Region- specific model for diagnostic criteria 
US  β sig level test of 
previous 
category 
global test trend test 
age <45 0 -  <0.001 <0.001 
 45-74 3.68 <0.001 <0.001   
 75+ 5.47 <0.001    
sex female 0 -    
 male 0.36 0.007    
diagnostic 
criteria  
before PVSG    <0.001 0.32 
 PVSG (1975) -0.8 <0.001 <0.001   
 WHO (2001) -1.46 <0.001    
constant  -15.9     
PA  β sig level test of 
previous 
category 
global test trend test 
age <45 0 -  <0.001 <0.001 
 45-74 3.47 <0.001    
 75+ 5.21 <0.001 <0.001   
sex female 0 -    
 male 0.46 0.001    
diagnostic 
criteria  
before PVSG  0 - <0.001 0.253 
 PVSG (1975) -0.68 <0.001    
 WHO (2001) -1.33 <0.001 <0.001   
constant  -15.8     
CA  β sig level test of 
previous 
category 
global test trend test 
age <45 0 -  <0.001 <0.001 
 45-74 3.67 <0.001    
 75+ 5.78 <0.001 <0.001   
sex female 0 -    
 male 0.36 0.026    
diagnostic 
criteria  
before PVSG 0 -  <0.001 0.478 
 PVSG (1975) -0.8 <0.001    
 WHO (2001) -1.52 <0.001 <0.001   
constant  -16.2     
 
 37 
From Table 21, we found after wide usage of Hydroxyurea for treating PV, PV mortality 
decreased significantly. The decrease in mortality in PA was less than that in CA and other area 
in the US. Also, from these three tables, in comparison to CA and other areas in the US, PA has a 
higher risk ratio of PV mortality among white males. In CA, people 75 and older had a higher 
mortality ratio than the same age group in PA and other areas of the US. 
 
Table 21: Region- specific model for treatment 
US  β sig level test of 
previous 
category 
global test trend test 
age <45 0 -  <0.001 <0.001 
 45-74 3.67 <0.001 <0.001   
 75+ 5.49 <0.001    
sex female 0 -    
 male 0.37 0.004    
Treatment before HU 0 -    
 HU (1987) -1.05 <0.001    
constant  -16.16     
PA  β sig level test of 
previous 
category 
global test trend test 
age <45 0 -  <0.001 <0.001 
 45-74 3.48 <0.001    
 75+ 5.2 <0.001 <0.001   
sex female 0 -    
 male 0.44 0.005    
Treatment before HU 0 -    
 HU (1987) -0.87 <0.001    
constant  -15.9     
CA  β sig level test of 
previous 
category 
global test trend test 
age <45 0 -  <0.001 <0.001 
 45-74 3.65 <0.001    
 75+ 5.74 <0.001 <0.001   
sex female 0 -    
 male 0.36 0.01    
Treatment before HU 0 -    
 HU (1987) -1.16 <0.001    
constant  -16.39     
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 3.2.4 Non-overlapping time period model 
After analyzing each time variable separately, we found that each was statistically significant 
with region, gender, and age in the model. We created a new time variable (seven segments) to 
include all these events in one model. Results are shown below (Table 22): PV mortality in PA 
was not statistically significant different from that in other parts of the US, while CA mortality 
was statistically significantly different from that in PA or other areas in the US. As people aged, 
PV mortality increased. White males have statistically significant higher rates than white 
females. The coefficients in the model are all negative, which indicates that PV mortality 
decreased from 1962 to 2009. By comparing with the previous time segment, we found that the 
acceptance of the PVSG criteria in 1975, the change from the ICD 8th to 9th revision in 1978, and 
the wide usage of Hydroxyurea in 1987 statistically significantly decreased PV mortality. The 
trend test was statistically significant, indicating that  PV mortality decreased from 1962 to 2009. 
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Table 22: Non-overlapping time period model 
  β sig level test of 
previous 
category 
global test trend test 
age <45 0 -  <0.001 <0.001 
 45-74 3.62 <0.001    
 75+ 5.55 <0.001 <0.001   
sex female 0 -  <0.001  
 male 0.37 <.001    
region US 0 -  0.03  
 PA 0.058 0.489    
 CA -0.16 0.04 <0.001   
Time 1962 0 -  <0.001 0.044 
 1968(ICD 
7th-8th) 
-0.07 0.541    
 1975(PVSG 
criteria) 
-0.25 0.044 <0.001   
 1978(ICD 
8th-9th) 
-0.83 <0.001 <0.001   
 1987(HU 
used) 
-1.1 <0.001 0.027   
 1999(ICD 
9th-10th) 
-1.3 <0.001 0.102   
 2001(WHO 
criteria) 
-1.5 <0.001 0.25   
constant  -15.91     
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4.0  DISCUSSION 
In the US population, age-adjusted PV mortality of males decreased after 1967, while that of 
females decreased after 1978. The rate among males was always higher than that of females. The 
age-specific PV mortality of males ages 45-74 continuously decreased over time, but that of 
males over 75-years-old increased from 1962 to 1974 and then decreased. The mortality rate of 
females ages 45-74 was stable from 1962 to 1978 and then quickly decreased, while that of 
females over 75-years-old increased from 1962 to 1978 and then decreased, similar to the pattern 
in males over 75. Ania reported in Olmsted County, Minnesota, that the PV age-adjusted 
incidence was 2.0, 1.1, 2.8, and 1.9 per 100,000 population per year in 1950-1959, 1960-1969, 
1970-1979, and 1980-1989, respectively. [16]This rate varied around the average incidence 1.9.[16] 
On the contrary, Berglund found the PV incidence rose in Malmo, Sweden, from 1950-1984, 
with decade specific rates of: 1.0, 1.6, 2.2, and 2.6 in 1950-1959, 1960-1969, 1970-1979, and 
1980-1984, respectively.[20] Similarly, Silverstein observed an increasing PV incidence (average 
is 1.6 per 100,000 population per year) in Rochester, Minnesota, from 1935 to 1969, though the 
number of cases (only 19) were too small to draw any conclusions about secular trend.[21] The 
average of age-adjusted mortality in the US is 0.21 per 100,000 population per year in males, and 
0.15 in females. Our result found PV had a decreasing mortality trend. Why our trend is different 
from above result possibly caused by the difference of methods. Both Ania and Berglund got 
their cases from the local medical records to diagnosed PV patients, but our data sources were 
drawn from the death certificates by MPDS system. Ania had 55 cases and Berglund had 177 
cases, but we had 18,743 cases. Obviously, difference in the sample size can lead to different 
statistical result. Berglund reported that the highest age-specific incidence occurred in males over 
80 years old and was 18.3/100,000 population per year, and the peak incidence in 70-79 year old 
females was 14.6/ 100,000 population per year. In our age-specific mortality analysis, we found 
the highest age-specific mortality rate similarly occurred in over 75-84 year old males and 
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females after 1977 but before that time in over 85 year old group. Additionally, Ania found in 
the Olmsted County analysis that the PV incidence of males was higher than that of females. Our 
model also showed a statistically significantly higher mortality rate in males. Berglund drew the 
conclusion that the increasing PV incidence was caused by increasing case ascertainment. It 
could be possible that in a similar manner, PV mortality is decreasing due to better treatment, as 
the survival time of treated patients is almost 10 times higher than those who are untreated. 
The table of death counts shows that 95% of deaths due to PV occur in whites.  In the 
age-adjusted mortality tables, we observed that the rates in non-whites are much lower than those 
in whites in the US population; there were many zero values in non-whites in the PA and CA 
populations. In an epidemiologic study of PV in Baltimore from 1950 to 1959, the PV incidence 
in African-Americans was 1.6 per million residents in the 10-year period, while that of whites 
was 4.3 per million. In this study, we found that PV deaths among non-whites are rare. In his 
paper, Modan said “The reported low frequency of polycythemia in Negroes is reflected in our 
findings, but the observed incidence, although only a third of that in whites is not as low as 
reported previously. In addition, as will be demonstrated below, polycythemia vera is more 
prevalent in the older age groups, where there are relatively less Negroes than whites.”  Although 
Modan said these words in 1965, life-expectancies of whites and non-whites are still statistically 
significantly different today. Additionally, differences in  medical care can lead to differences in 
mortality rates between whites and non-whites. In short, the small numbers of PV deaths among 
non-whites found in this study may reflect a complex interaction of factors.  
In the non-overlapping models, we found no statistically significant difference in PV 
mortality between PA and other parts of the US, and the coefficients of PA in the model were 
positive. This indicates that the pattern of PV deaths in PA is not different from that of other 
parts of the US. However, we observed that PA males had higher PV age-adjusted mortality 
compared with CA and other areas of the US before the ICD code revision change in 1978.  
Our time period analysis, corresponding to changes in ICD coding, diagnostic criteria, 
and implementation of Hydroxyurea as standard treatment, found that all of these variables 
significantly influenced PV mortality. The overlapping time periods made these models difficult 
to fit. If we included all three time variables in one model, the overlapping time periods could 
lead to poor statistical significance for some variables; on the contrary, if we included only one 
time variable in the model, we risked ignoring important predictors. To solve this problem, we 
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built a model including all of the time period changes by dividing the timeline into seven 
segments, and found that ICD 8th to 9th revision, acceptance of PVSG criteria, and Hydroxyurea 
usage were time points when PV mortality significantly decreased. Then we compared these 
results with the three time specific variables, and found the model including all of the time 
periods had fewer statistically significant changes.  In the one-time-factor models, except for the 
ICD 6&7th to 8th revision change, other time categories were statistically significant when 
compared with earlier time periods. We also compared the model with the adjusted mortality 
table of the US (Fig 2). Based on all of the findings, we concluded that the 8th to the 9th ICD 
codes revision (in 1978) significantly reduced PV mortality, and the acceptance of the PVSG 
diagnostic criteria (in 1975) significantly reduced the difference of PV mortality between males 
and females. Moreover, the widespread usage of Hydroxyurea in 1987 helped to statistically 
significantly reduce PV mortality. 
From the age-adjusted mortality table of US males and females, we observed a drop in 
1978 when the ICD code changed from the 8th to 9th revision. As it influenced both genders in 
PV was classified as a “malignant neoplasm” before the 9th revision ICD was introduced in 1979 
and in the 9th and 10th revisions it was classified as a “benign neoplasm and neoplasm of 
uncertain behavior and of unspecified nature”. In 1978, the age-adjusted PV mortality of US 
males was 0.28 per 100,000 population per year, and the rate in females was 0.22 per 100,000 
population per year. However in 1979, the rates in males and females were 0.17 and 0.14 per 
100,000 population per year, respectively. The change in ICD revision does appear to have 
influenced PV mortality directly.  From the time period 1975-1977 to the period 1978-1987, it is 
observed that for people under 75 there is a 50% decrease in age-specific mortality in both males 
and females. Between the same two time periods, there was a 25% decrease in the mortality rate 
seen in 75+ males and a 30% decrease in 75+ females. The 8th to 9th ICD revision change 
influenced the mortality rates in younger people more than older people. . Identifying this 
discontinuity may help other PV researchers avoid bias when analyzing long-term mortality 
trends. 
After the 1975 PVSG diagnostic criteria were introduced, the major diagnostic criteria 
required for diagnosis increased from one to three. Etiology of other polycythemia was ruled out, 
and evidence of myeloproliferative disorder was needed.  After these criteria were accepted, the 
difference in PV mortality between males and females decreased quickly. From the age-specific 
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mortality tables, we found that this decrease was caused by a large decrease in the mortality rate 
among 45-74 year old males and a small increase in the rate in 75+ year old females. In the 
1968-1974 time period, age-adjusted rate in white male was 0.92 per 100,000 population per 
year, while in the 1975-1977 time period, this value was 0.59 per 100,000 population per year. 
At the same time, the rate in 75+ year old females changed from 2.01 to 2.21 per 100,000 
population per year. The rate in 75+ year old males slightly decreased while that in other female 
groups did not change. We also know that the PVSG began in 1967 and did a series of clinical 
trials to determine the most appropriate diagnostic criteria and treatment for PV.  Because we 
know the diagnostic criteria were designed to reduce false positive diagnoses after 1975, and we 
observed a decline in the difference between PV mortality of two genders, it is possible that 
males had more false-positive PV diagnoses than females before 1975. It was reported that 
secondary polycythemia, caused mainly by smoking or high blood pressure, can lead to false-
positive diagnosis of PV. Because males were more likely to be smokers in this time period, the 
declining difference in PV mortality between the genders may have been caused by more false-
positive cases in males being excluded. 
Limitations of this research include those that existed in the source data. The data in this 
study were generated using the MPDS system, which was based on death certificates in the 
NCHS repository. Because PV patients mainly die from thrombosis if untreated, some PV 
patients’ deaths may be recorded in other underlying causes of death categories, such as 
cardiovascular disease.[15] Furthermore, PV patients could develop myelofibrosis or acute 
myeloid leukemia (AML) as their disease progresses. In these situations, the underlying causes 
of deaths would not be PV despite its strong association with those diseases. These limitations in 
cause of death coding and reporting may have underestimated PV mortality. 
In the other similar epidemiology research about cause-specific mortality trends, 
especially in cancers, Poisson models were widely used to model the count of death with an 
offset of population in the year. However, our research found that the Poisson model did not fit 
the data because of serious over dispersion. After examining the possible use of the  over-
dispersed Poisson model and negative binomial model, we finally picked the second one as it had 
relative smaller AIC and BIC values. Although no direct method to check the fit exists, we found 
that the modeling results matched the age-adjusted graphs well. We found a lessening of the 
difference in PV mortality between males and females after the acceptance of the 1975 PVSG 
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diagnostic criteria, a decrease in mortality from the ICD 8th to 9th ICD revision, and a slow, 
steady decline in mortality  after Hydroxyurea became widely used in 1987, in both the non-
overlapping model and the age-adjusted graphs. Furthermore, males had statistically significantly 
higher mortality than females. In short, our model fits these data well.  
Although some limitations exist, this study is the first attempt to examine PV mortality in 
PA and the US over an almost 50-year period. Previous population-based studies of PV mortality 
have used only local populations with small sample sizes. The present study included 18,743 
cases and offered a more complete and comprehensive examination of PV mortality than any 
other to date.  
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5.0  CONCLUSION 
 
This study is the first comprehensive examination of PV mortality rates over time in the US and 
PA. We found that PV age-adjusted mortality in US males increased from 1962 to 1967, then 
decreased after 1967 while of the mortality rate in US females variedwas relatively stable at first 
then decreased after 1978.  PV death patterns in PA and the US were not statistically 
significantly different. In the US, PV mortality of males was statistically significantly higher 
than that of females, while in PA there was higher mortality in males compared with females. 
After consideration of possible influences on PV mortality rates, we determined that the 
acceptance of the PVSG diagnostic criteria in 1975 decreased the magnitude of the difference in 
PV mortality between males and females seen prior to 1975, apparently due to the introduction 
of sex-specific red cell mass values. The transition from the 8th to the 9th ICD death code revision 
in 1979 decreased PV mortality significantly in both males and females. While the specificity of 
the code remained the same from the 8th to 9th revision, PV was one of several malignancies 
changed to “benign” and/or “uncertain and unspecified behavior” in the 9th revision. This may 
have had an effect on mortality coding and subsequent effect on mortality rates. 
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APPENDIX A 
SUMMARY OF DEATH COUNT 
Table 23 Summary of death count 
WM < 45 WM 45-74 WM >75 WF < 45 WF 45-74 WF >75 NWM < 45 NWM 45-74 NWM >75 NWF< 45 NWF 45-74 NWF >75
US PA CA US PA CA US PA CA US PA CA US PA CA US PA CA US PA CA US PA CA US PA CA US PA CA US PA CA US PA CA
1962 19 1 2 202 17 13 49 1 6 14 0 0 105 5 9 44 3 3 0 0 0 5 0 0 1 0 0 0 0 0 5 0 0 0 0 0
1963 16 2 0 189 13 14 42 2 2 7 0 0 131 10 12 58 2 4 4 0 0 12 0 1 1 0 0 0 0 0 8 1 0 1 0 0
1964 17 3 2 184 11 15 62 4 8 7 0 0 121 6 7 71 4 5 1 0 0 6 1 0 0 0 0 2 0 0 4 0 0 0 0 0
1965 19 2 3 198 19 15 61 2 7 4 0 0 124 8 11 67 7 8 8 2 0 22 2 1 1 0 0 1 0 0 11 0 1 0 0 0
1966 18 0 1 219 28 20 58 5 7 9 0 2 111 6 7 53 4 5 3 0 0 8 1 0 2 0 1 0 0 0 11 0 1 2 0 0
1967 10 1 2 249 29 17 68 4 8 10 2 1 112 7 4 76 6 5 1 0 0 10 1 1 3 0 0 1 0 0 5 0 0 2 0 0
1968 23 1 1 203 15 9 77 2 3 8 0 0 108 9 8 69 6 10 2 0 0 7 0 0 2 0 0 0 0 0 6 0 0 1 0 0
1969 15 2 0 235 14 23 75 4 5 8 0 1 158 2 22 104 6 12 2 0 0 14 0 0 2 0 0 0 0 0 5 0 1 1 0 0
1970 10 0 2 218 15 12 69 6 8 9 1 0 134 13 6 77 4 13 3 0 1 14 2 2 2 1 0 0 0 0 4 0 0 1 0 0
1971 19 2 1 223 22 10 66 2 6 7 1 0 128 5 10 107 6 16 1 0 0 9 0 0 1 0 0 0 0 0 8 0 1 0 0 0
1972 19 1 1 210 16 13 67 2 10 1 0 0 141 6 12 108 9 5 3 0 1 16 0 1 0 0 0 0 0 0 6 1 0 2 0 1
1973 12 1 2 184 9 13 69 2 7 9 1 0 113 10 14 89 8 10 2 0 0 11 0 1 4 0 0 1 0 0 7 0 0 1 0 0
1974 18 0 3 182 14 15 75 7 7 5 0 0 111 4 8 108 8 16 4 0 1 3 0 1 3 0 1 1 0 0 9 1 0 5 0 0
1975 12 1 1 149 9 14 85 7 11 3 0 1 128 3 10 118 5 13 2 0 0 9 1 0 2 0 0 2 0 0 3 0 0 3 0 1
1976 6 0 0 155 14 12 56 4 5 9 0 0 119 6 8 111 4 17 4 0 0 6 0 0 1 0 0 1 0 0 4 0 0 3 1 0
1977 7 0 1 130 8 10 78 2 9 9 1 1 143 6 9 122 4 13 1 0 0 10 0 2 5 0 0 0 0 0 6 1 0 2 0 0
1978 12 1 0 144 14 9 78 5 13 9 2 3 114 7 12 137 9 13 1 0 1 8 0 0 3 0 0 1 0 0 2 0 1 4 0 0
1979 5 0 0 79 2 4 55 5 7 4 0 1 83 5 10 89 3 3 0 0 0 3 2 0 2 1 0 0 0 0 4 0 0 3 0 0
1980 9 0 2 88 6 7 54 5 5 1 0 0 74 4 4 100 8 14 3 0 0 5 0 2 4 0 0 1 0 0 9 0 2 3 0 0
1981 7 1 0 82 2 5 49 3 4 2 0 0 53 4 6 109 11 9 0 0 0 0 0 0 2 0 1 0 0 0 5 0 0 4 0 2
1982 2 2 0 85 4 9 66 6 5 3 0 1 57 3 2 98 8 8 2 0 0 7 0 0 2 0 0 0 0 0 4 0 0 4 0 0
1983 5 0 0 84 8 6 75 4 11 1 0 0 71 5 6 110 7 14 1 0 1 6 0 2 2 0 0 0 0 0 2 1 0 2 1 0
1984 3 0 0 67 4 4 63 4 6 2 0 0 56 2 8 113 6 13 2 0 0 14 0 1 3 1 0 0 0 0 4 0 0 3 0 1
1985 4 1 0 70 8 4 65 5 7 4 1 0 60 1 7 96 4 11 0 0 0 3 0 1 1 0 1 0 0 0 4 0 0 3 0 0
1986 1 0 0 56 6 4 75 3 5 2 0 0 60 5 2 103 4 15 0 0 0 6 0 0 6 0 0 0 0 0 7 1 0 6 1 0
1987 4 0 0 65 4 12 68 1 4 3 0 0 53 4 4 90 4 5 0 0 0 5 0 0 2 0 0 0 0 0 3 0 0 3 0 0
1988 1 0 0 63 4 6 66 2 8 2 1 1 58 2 7 93 5 9 0 0 0 3 0 0 5 0 0 0 0 0 9 0 1 5 0 0
1989 7 1 1 85 3 8 58 6 6 1 0 0 70 2 10 120 8 15 1 0 0 4 0 0 5 0 1 0 0 0 4 0 0 4 0 0
1990 1 0 0 46 3 3 63 1 6 3 0 0 55 6 2 123 3 10 0 0 0 7 0 0 1 0 0 0 0 0 12 2 0 3 0 0
1991 1 0 1 73 4 9 81 3 6 0 0 0 58 2 6 133 10 3 0 0 0 2 0 0 4 0 0 1 0 0 4 3 0 7 2 0
1992 3 0 0 58 4 3 67 2 6 1 0 0 39 3 3 151 11 17 0 0 0 9 0 2 1 0 0 0 0 0 3 0 1 5 0 0
1993 3 0 0 54 4 7 69 6 4 2 0 0 38 0 3 149 14 15 2 0 0 8 0 2 1 0 1 0 0 0 7 1 1 7 1 0
1994 1 0 0 55 4 2 88 2 7 1 0 1 39 4 0 110 10 11 2 0 0 6 1 1 6 2 0 0 0 0 6 1 0 3 1 0
1995 0 0 0 48 3 3 85 3 9 1 0 0 38 1 2 133 11 8 1 0 1 6 0 0 2 0 0 0 0 0 2 0 0 8 0 0
1996 1 0 0 64 3 5 88 5 9 1 0 0 28 4 4 148 17 8 1 0 1 5 0 0 4 0 2 1 0 0 5 1 0 11 1 3
1997 2 0 0 39 1 3 76 6 1 2 1 0 44 5 5 153 7 18 0 0 0 6 0 1 2 0 0 1 0 0 4 0 0 4 0 0
1998 2 0 0 65 3 4 82 5 5 1 0 0 49 7 4 145 10 14 2 0 1 3 1 0 4 1 0 1 0 0 4 1 1 3 0 0
1999 2 0 0 39 4 2 81 3 6 1 0 0 45 1 3 132 5 13 1 0 0 5 0 0 3 0 1 0 0 0 6 0 0 5 2 0
2000 4 0 0 43 3 2 87 8 7 1 0 0 40 1 3 136 9 5 0 0 0 3 0 0 4 0 1 1 0 0 3 0 0 4 0 0
2001 6 0 0 51 2 7 86 5 8 2 0 0 56 2 4 128 5 12 0 0 0 3 0 0 3 0 1 0 0 0 5 0 2 4 0 1
2002 3 1 0 46 2 2 80 6 10 3 0 0 30 3 0 134 5 19 1 0 0 3 0 0 5 0 0 1 0 0 4 1 0 7 1 0
2003 3 0 0 59 1 9 75 2 12 0 0 0 36 2 1 117 6 12 1 0 1 5 0 0 2 0 1 1 0 0 3 0 2 7 0 0
2004 3 0 0 51 2 1 85 3 9 3 0 0 33 0 1 114 9 9 0 0 0 3 0 1 2 0 1 1 0 0 1 0 0 8 0 1
2005 1 0 0 37 1 3 80 2 9 0 0 0 27 0 2 131 6 10 0 0 0 3 0 1 5 0 2 0 0 0 1 0 0 5 1 2
2006 1 0 0 44 3 4 66 3 4 2 1 0 32 1 3 119 5 10 1 0 0 1 1 0 3 1 0 0 0 0 2 1 0 10 1 4
2007 3 0 1 45 3 3 80 4 11 0 0 0 30 0 3 111 3 9 1 0 0 3 0 0 4 1 0 0 0 0 2 0 1 4 0 1
2008 2 0 1 32 3 2 77 9 6 1 0 0 31 1 0 103 8 10 2 0 0 4 0 0 2 0 1 0 0 0 4 0 0 6 0 2
2009 2 0 1 42 1 4 73 6 3 2 1 0 30 1 1 100 9 6 1 0 0 4 1 0 3 0 0 0 0 0 1 0 0 2 0 0  
 47 
APPENDIX B 
AGE SPECIFIC MORTALITY 
Table 24  Age-specific mortality of US white males 
 1962 -1967 1968-1974 1975-1977 1978-1986 1987-1998 1999-2000 2001-2009 
45 to 54 0.42 0.38 0.16 0.08 0.04 0.03 0.04 
55 to 64 1.09 1 0.65 0.28 0.18 0.12 0.11 
65 to 74 1.79 1.85 1.31 0.83 0.54 0.48 0.35 
75 to 84 2.46 2.68 2.41 1.74 1.47 1.25 1.05 
85 plus 1.6 2.41 2.38 2.23 2.68 2.82 2.06 
less than 
45 
0.03 0.03 0.01 0.01 0 0 0 
45 to 74 0.95 0.92 0.6 0.34 0.21 0.16 0.12 
75 plus 2.32 2.63 2.41 1.84 1.7 1.57 1.27 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 25 Age-specific mortality of US white females 
 1962 -1967 1968-1974 1975-1977 1978-1986 1987-1998 1999-2000 2001-2009 
45 to 54 0.2 0.16 0.15 0.05 0.02 0.03 0.01 
55 to 64 0.44 0.47 0.45 0.15 0.1 0.12 0.08 
65 to 74 1.15 1.07 1.07 0.61 0.39 0.33 0.28 
75 to 84 1.85 2.12 2.32 1.47 1.28 1.08 0.79 
85 plus 1.33 1.61 1.86 2.23 2.37 2.63 2.11 
less 
than 45 
0.02 0.01 0.01 0 0 0 0 
45 to 74 0.51 0.49 0.5 0.25 0.15 0.13 0.09 
75 plus 1.75 2.02 2.22 1.66 1.58 1.53 1.2 
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 Table 26 Age-specific mortality of PA white males 
 1962 -1967 1968-1974 1975-1977 1978-1986 1987-1998 1999-2000 2001-2009 
45 to 54 0.41 0.41 0.32 0.08 0.02 0 0.03 
55 to 64 1.79 1 0.77 0.35 0.08 0.14 0.17 
65 to 74 2.41 2.12 1.15 0.91 0.68 0.67 0.2 
75 to 84 2.07 2.16 1.82 2.13 1.15 1.32 0.98 
85 plus 0.68 1.51 5.11 2.64 1.94 3.3 2.52 
less than 
45 
0.04 0.03 0.01 0.02 0 0 0 
45 to 74 1.32 0.98 0.67 0.4 0.23 0.21 0.11 
75 plus 1.86 2.06 2.41 2.22 1.29 1.7 1.32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 27 Age-specific mortality of PA white females 
 1962 -1967 1968-1974 1975-1977 1978-1986 1987-1998 1999-2000 2001-2009 
45 to 54 0.14 0.06 0.05 0.1 0.01 0 0.03 
55 to 64 0.54 0.35 0.21 0.22 0.08 0.06 0.05 
65 to 74 0.74 1.04 0.71 0.38 0.44 0.53 0.12 
75 to 84 1.78 2.45 1.17 1.64 1.65 0.58 0.78 
85 plus 1.87 1.73 1.83 2.01 2.43 3.62 1.69 
less than 
45 
0.01 0.01 0.01 0.01 0.01 0 0.01 
45 to 74 0.42 0.4 0.28 0.23 0.18 0.17 0.06 
75 plus 1.8 2.31 1.32 1.73 1.85 1.43 1.06 
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 Table 28 Age-specific mortality of CA white males 
 1962 -
1967 
1968-1974 1975-1977 1978-1986 1987-1998 1999-2000 2001-2009 
45 to 54 0.29 0.21 0.1 0.06 0.04 0 0.03 
55 to 64 0.68 0.67 0.35 0.16 0.18 0.07 0.11 
65 to 74 2.03 1.37 1.54 0.62 0.49 0.28 0.26 
75 to 84 3 2.94 3.26 1.81 1.24 0.94 0.98 
85 plus 2.99 1.33 1.92 3.56 1.7 1.43 2.43 
less than 
45 
0.03 0.02 0.01 0 0 0 0 
45 to 74 0.78 0.6 0.5 0.23 0.19 0.08 0.1 
75 plus 3 2.66 3.01 2.15 1.33 1.04 1.32 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 29 Age-specific mortality of CA white females 
 1962 -
1967 
1968-1974 1975-1977 1978-1986 1987-1998 1999-2000 2001-2009 
45 to 54 0.03 0.16 0.09 0.04 0.03 0.02 0.01 
55 to 64 0.46 0.53 0.29 0.13 0.09 0 0.05 
65 to 74 0.88 0.88 0.78 0.59 0.34 0.35 0.09 
75 to 84 1.49 2.82 2.31 1.57 1.1 0.62 0.87 
85 plus 1.55 2.36 4.47 2.62 2.22 2.63 1.73 
less than 
45 
0.01 0 0.01 0.01 0 0 0 
45 to 74 0.38 0.45 0.33 0.22 0.13 0.09 0.04 
75 plus 1.5 2.73 2.82 1.85 1.41 1.19 1.14 
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